Literature DB >> 10596701

Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant.

G C Riise1, B A Andersson, C Kjellström, G Martensson, F N Nilsson, W Ryd, H Scherstén.   

Abstract

The major cause of mortality in the long-term in lung transplant recipients is chronic rejection. This is a fibroproliferative process in the small airways leading to obliterative bronchiolitis and progressive loss of lung function, both constituting the clinical entity bronchiolitis obliterans syndrome (BOS). Granulocyte activation has been implicated as one factor behind BOS. Granulocyte markers in bronchoalveolar lavage (BAL) fluid were prospectively and longitudinally studied in order to identify possible association with BOS. BAL fluid from 266 bronchoscopy procedures performed in twelve single lung, eight bilateral lung and five heart/lung transplant recipients were analysed. The majority (19 of 25) were studied for a period of 2 yrs after surgery. Myeloperoxidase (MPO), eosinophil cationic protein (ECP) and interleukin-8 (IL-8) levels were used as indirect markers of activation and attraction of granulocytes. Five patients developed BOS. Ninety-eight episodes of acute rejection, nine of bacterial infection, 19 of cytomegalovirus pneumonitis, nine of Pneumocystis carinii infection, two of aspergillus infection and two of respiratory syncytial virus infection were diagnosed. BOS patients had significantly higher mean levels of MPO, ECP and IL-8 compared to patients without BOS, irrespective of acute rejection status. Over time, the five patients with BOS had significantly elevated BAL fluid levels of MPO and ECP as well as neutrophil percentages, and in four patients this increase preceded the clinical diagnosis of BOS by several months. Elevated bronchoalveolar lavage fluid neutrophil percentage as well as levels of the granulocyte activation markers myeloperoxidase and eosinophil cationic protein appear to be early signs of development of BOS in lung transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596701     DOI: 10.1183/09031936.99.14511239

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

Review 1.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

Review 2.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 3.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

4.  Human neutrophil peptide in lung chronic allograft dysfunction.

Authors:  Cavan Reilly; Tereza Cervenka; Marshall I Hertz; Trisha Becker; Chris H Wendt
Journal:  Biomarkers       Date:  2011-10-11       Impact factor: 2.658

5.  Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Brigitte Gomperts; Ying Ying Xue; Kurt Hong; Javier Mestas; Abbas Ardehali; Borna Mehrad; Rajan Saggar; Joseph P Lynch; David J Ross; Robert M Strieter
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Aspiration, localized pulmonary inflammation, and predictors of early-onset bronchiolitis obliterans syndrome after lung transplantation.

Authors:  P Marco Fisichella; Christopher S Davis; Erin Lowery; Luis Ramirez; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Am Coll Surg       Date:  2013-04-28       Impact factor: 6.113

7.  Alcohol ingestion by donors amplifies experimental airway disease after heterotopic transplantation.

Authors:  Patrick O Mitchell; David M Guidot
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

Review 8.  Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome.

Authors:  V E Kennedy; J L Todd; S M Palmer
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

Review 9.  Bronchiolitis obliterans.

Authors:  Petey Laohaburanakit; Andrew Chan; Roblee P Allen
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

10.  Protein-DNA array-based identification of transcription factor activities differentially regulated in obliterative bronchiolitis.

Authors:  Ming Dong; Xin Wang; Hong-Lin Zhao; Yu-Xia Zhao; Ya-Qing Jing; Jing-Hua Yuan; Yi-Jiu Guo; Xing-Long Chen; Ke-Qiu Li; Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.